Yuki Abe

1.8k total citations · 1 hit paper
25 papers, 1.1k citations indexed

About

Yuki Abe is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Yuki Abe has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Oncology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Yuki Abe's work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Cancer therapeutics and mechanisms (7 papers). Yuki Abe is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Cancer therapeutics and mechanisms (7 papers). Yuki Abe collaborates with scholars based in Japan, Germany and United States. Yuki Abe's co-authors include Takashi Nakada, Junko Yamaguchi, Yusuke Ogitani, Toshinori Agatsuma, Masataka Oitate, Tetsuo Aida, Masako Soma, Shingo Arakawa, Ryo Atsumi and Katsunobu Hagihara and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Yuki Abe

23 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

2016 767 citations Yusuke Ogitani, Tetsuo Aida et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yuki Abe Japan	10	892	560	296	281	77	25	1.1k
Takashi Nakada Japan	7	1.1k 1.2×	677 1.2×	383 1.3×	274 1.0×	66 0.9×	14	1.3k
Joshua Z. Drago United States	9	742 0.8×	454 0.8×	255 0.9×	356 1.3×	95 1.2×	28	1.1k
Naoya Harada Japan	6	711 0.8×	475 0.8×	313 1.1×	173 0.6×	45 0.6×	7	881
Masako Soma Japan	4	689 0.8×	413 0.7×	251 0.8×	159 0.6×	51 0.7×	5	790
Vivian Ng United States	7	709 0.8×	376 0.7×	404 1.4×	205 0.7×	50 0.6×	10	955
Marianela Pérez-Torres United States	8	816 0.9×	413 0.7×	369 1.2×	483 1.7×	59 0.8×	13	1.1k
Natalia Sergina United States	9	866 1.0×	489 0.9×	252 0.9×	681 2.4×	70 0.9×	9	1.3k
Yu-Waye Chu United States	5	992 1.1×	738 1.3×	133 0.4×	204 0.7×	85 1.1×	5	1.2k
Sara Kenkare-Mitra United States	4	1.0k 1.1×	847 1.5×	154 0.5×	426 1.5×	111 1.4×	5	1.3k
Thinh Q. Pham United States	8	913 1.0×	411 0.7×	303 1.0×	629 2.2×	82 1.1×	10	1.3k

Countries citing papers authored by Yuki Abe

Since Specialization

Citations

This map shows the geographic impact of Yuki Abe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuki Abe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuki Abe more than expected).

Fields of papers citing papers by Yuki Abe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuki Abe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuki Abe. The network helps show where Yuki Abe may publish in the future.

Co-authorship network of co-authors of Yuki Abe

This figure shows the co-authorship network connecting the top 25 collaborators of Yuki Abe. A scholar is included among the top collaborators of Yuki Abe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuki Abe. Yuki Abe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Takahashi, Keiko, Yoshinobu Shiose, M Yamada, et al.. (2025). DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity. Molecular Cancer Therapeutics. 25(1). 7–20. 1 indexed citations

Takahashi, Kazuki, Yoshinobu Shiose, Wataru Obuchi, et al.. (2024). Abstract 6579: DS-3939a, a novel TA-MUC1-targeting antibody-drug conjugate (ADC) with a DNA topoisomerase I inhibitor DXd, exhibits potent antitumor activity in preclinical models. Cancer Research. 84(6_Supplement). 6579–6579. 1 indexed citations

Saito, C., Yumi Nishiya, Tomomichi Ishizaka, et al.. (2024). Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models. Molecular Cancer Therapeutics. 23(3). 257–271. 17 indexed citations

Nagata, Morio, Yuki Kaneda, K. Honda, et al.. (2021). 10P DS-6000a, a novel CDH6-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models. Annals of Oncology. 32. S363–S364. 5 indexed citations

Banjo, Toshihiro, Yoshimi Takata, Daisuke Honma, et al.. (2021). EZH1/2 Dual Inhibitor Valemetostat Tosylate (DS-3201b) Acts Differently from EZH2 Selective Inhibitor on Epigenetic Landscape to Exert Greater Anti-Tumor Effect Against Diffuse Large B-Cell Lymphoma. Blood. 138(Supplement 1). 2948–2948. 1 indexed citations

Nagamoto, Yasuhito, Takahiro Jimbo, Takeshi Isoyama, et al.. (2020). 11P Preclinical evaluation of DS-2087b, a novel and selective inhibitor of EGFR/HER2 exon 20 insertions. Annals of Oncology. 31. S248–S248. 9 indexed citations

Yamaguchi, Junko, Tomoko Shibutani, Satoru Yasuda, et al.. (2019). Abstract C026: DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models. Molecular Cancer Therapeutics. 18(12_Supplement). C026–C026. 1 indexed citations

Abe, Yuki, Takashi Nakada, & Toshinori Agatsuma. (2019). Development of novel DNA topoisomerase I inhibitor based ADC technology. Drug Delivery System. 34(1). 52–58.

Yasuda, Satoru, Yusuke Yokouchi, Ken Sakurai, et al.. (2018). Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd.. Journal of Clinical Oncology. 36(15_suppl). e24206–e24206. 14 indexed citations

10.

Hayashi, Hidemi, Shinya Abe, Hideki Yagi, et al.. (2018). Anti‐tumor effects of mAb against l‐type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes. Cancer Science. 110(2). 674–685. 26 indexed citations

11.

Hirotani, Kenji, Reimar Abraham, Sabine Blum, et al.. (2017). Abstract 3092: U3-1402a, a novel HER3-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent antitumor efficacy. Cancer Research. 77(13_Supplement). 3092–3092. 4 indexed citations

12.

Ogitani, Yusuke, Tetsuo Aida, Katsunobu Hagihara, et al.. (2016). DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clinical Cancer Research. 22(20). 5097–5108. 767 indexed citations breakdown →

13.

Nakada, Takashi, Takeshi Masuda, Hiroyuki Naito, et al.. (2016). Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorganic & Medicinal Chemistry Letters. 26(6). 1542–1545. 119 indexed citations

14.

Ogitani, Yusuke, Yuki Abe, Takuma Iguchi, et al.. (2016). Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology. Bioorganic & Medicinal Chemistry Letters. 26(20). 5069–5072. 35 indexed citations

15.

Abe, Yuki, et al.. (2014). Tolerant Sharing of a Single-user Application Among Multiple Users in Collaborative Work.

16.

Perkins, Stephen J., Ruodan Nan, Keying Li, Sanaullah Khan, & Yuki Abe. (2011). Analytical ultracentrifugation combined with X-ray and neutron scattering: Experiment and modelling. Methods. 54(1). 181–199. 27 indexed citations

17.

Abe, Yuki, et al.. (2010). Using the Model Checker Spin for Web Application Design. 137–140. 3 indexed citations

18.

Baba, Satoshi, Yuki Abe, Toshihiro Suzuki, et al.. (2009). Improvement of compactin (ML-236B) production by genetic engineering in compactin high-producing Penicillium citrinum. Applied Microbiology and Biotechnology. 83(4). 697–704. 13 indexed citations

19.

Nishida, Kento, Kiminobu Yonemura, Yuki Abe, & Katsumasa Takagi. (1995). Antitumor effects of liposomes containing adriamycin on chemically-induced rat malignant fibrous histiocytoma.. PubMed. 69(5). 322–31. 1 indexed citations

20.

Katada, Motomi, et al.. (1990). Studies on chemical state of iron-barium glaze. II. Reaction in iron-barium glaze on heating.. NIPPON KAGAKU KAISHI. 150–154. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact